p75ECD Peptide Therapy for Alzheimer's Neurodegeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective diagnostic and therapeutic solutions for neurological disorders such as Alzheimer's Disease and cerebral amyloid angiopathy, particularly in addressing the imbalance of p75 and its extracellular domain, which is linked to neurodegeneration.
Innovation Solution
A method involving the measurement of p75 extracellular domain (p75ECD) and full-length p75 levels in biological samples to diagnose and prognose Alzheimer's Disease, and administering p75ECD or its derivatives to treat and prevent neurological disorders by restoring neuroprotective balance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If p75ECD is administered to treat neurological disorders, then neurodegeneration is reduced and cognitive functions improve, but the complexity of diagnostic and therapeutic intervention increases
Solution Approach 1:
The patent extracts the extracellular domain (p75ECD) from the full-length p75 receptor protein to create a therapeutic agent. This extracted domain specifically binds to amyloid-beta peptides, neutralizing their neurotoxic effects without requiring the complete receptor structure, thereby simplifying the therapeutic intervention while maintaining effectiveness
Solution Approach 2:
p75ECD serves as an intermediary molecule that mediates between the harmful amyloid-beta peptides and the neuronal cells. It binds to Aβ peptides in the extracellular space, preventing direct interaction between Aβ and neuronal receptors, thus protecting neurons from toxicity while maintaining a relatively simple intervention approach
2Measurement precision
If p75ECD levels are measured to diagnose Alzheimer's Disease, then diagnostic accuracy improves, but the difficulty of detecting and measuring increases
Solution Approach 1:
The patent uses antibodies that specifically recognize and bind to p75ECD as detection tools. These antibodies act as copies or proxies that can be easily measured through standard immunoassay techniques, allowing indirect but accurate measurement of p75ECD levels in biological samples without requiring direct complex measurement of the peptide itself
Solution Approach 2:
The patent measures p75ECD levels as a quantitative parameter that changes in response to Alzheimer's disease pathology. By establishing baseline levels in healthy individuals and comparing them to patient levels, the method transforms a complex biological measurement into a simple comparative quantitative assessment that improves diagnostic accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate diagnosis and potential treatment of Alzheimer's Disease and other neurodegenerative conditions by measuring p75ECD levels and using p75ECD to reduce neurodegeneration and improve cognitive functions.
Implementation Method 1
p75ECD, a soluble form of the p75 neurotrophin receptor, has been shown to bind to amyloid-β (Aβ) peptides
Implementation Method 2
p75 undergoes extracellular domain (or ectodomain) shedding, wherein the extracellular domain of p75 (p75ECD) is cleaved from the full length protein. p75ECD shedding is physiologically regulated by tumor necrosis factor-alpha-converting enzyme (TACE)
Data Source
AI summary
A method of treating and/or preventing neurological conditions, comprising administering to a subject in need thereof a therapeutically effective amount of a p75 extracellular domain (p75ECD) or a functional fragment, variant, analogue or derivative thereof. Also provided is a method of diagnosing and/or prognosing Alzheimer's disease (AD) in a test subject comprising comparing the concentration of p75ECD and/or p75FL and/or the ratio of p75ECD:p75FL in a biological sample of the test subject to non-demented control subject(s).